COVID-19 mRNA vaccination status and concerns among pregnant women in Japan: a multicenter questionnaire survey

• Egile Nagusiak: Ken Takahashi (Egilea), Osamu Samura (Egilea), Akihiro Hasegawa (Egilea), Haruna Okubo (Egilea), Keiji Morimoto (Egilea), Madoka Horiya (Egilea), Aikou Okamoto (Egilea), Daigo Ochiai (Egilea), Mamoru Tanaka (Egilea), Masaki Sekiguchi (Egilea), Naoyuki Miyasaka (Egilea), Yuto Suzuki (Egilea), Tsutomu Tabata (Egilea), Eijiro Hayata (Egilea), Masahiko Nakata (Egilea), Tomoo Suzuki (Egilea), Hirotaka Nishi (Egilea), Yumi Toda (Egilea), Shinji Tanigaki (Egilea), Natsumi Furuya (Egilea), Junichi Hasegawa (Egilea), Shunsuke Tamaru (Egilea), Yoshimasa Kamei (Egilea), Seisuke Sayama (Egilea), Takeshi Nagamatsu (Egilea), Yuka Otera Takahashi (Egilea), Michihiro Kitagawa (Egilea), Tatsuya Arakaki (Egilea), Akihiko Sekizawa (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2023-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background mRNA vaccination is an effective, safe, and widespread strategy for protecting pregnant women against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, information on factors such as perinatal outcomes, safety, and coverage of mRNA va...